What Is Noveltreat? Sun Pharma's Generic Semaglutide for Weight Loss in India
Noveltreat is Sun Pharma's DCGI-approved generic semaglutide injection for chronic weight management in India. Here is the complete guide: how it works, dosing, results, and side effects.
If your doctor has just prescribed Noveltreat, or if you have heard about it and want to know more, you are not alone. A lot of people feel a little confused when they first hear words like "semaglutide" or "GLP-1 injection." The good news is that Noveltreat is much simpler to understand than it sounds.
This guide walks through everything you need to know - in plain language - so you can start your treatment feeling informed and confident.
What is Noveltreat?
Noveltreat is Sun Pharma's brand name for a medicine called semaglutide. It is a once-weekly injection approved by India's drug regulator, the Drugs Controller General of India (DCGI), for chronic weight management in adults - as an adjunct to a reduced-calorie diet and increased physical activity.
It was developed by Sun Pharma, India's largest pharmaceutical company, and became available after the semaglutide patent expired in India on March 20, 2026.
Noveltreat belongs to a group of medicines called GLP-1 receptor agonists. GLP-1 is a natural hormone your gut releases after you eat. It tells your brain that you are full, slows how quickly food leaves your stomach, and helps manage your blood sugar.
When you take Noveltreat, it works like that natural hormone - but the effect lasts much longer. This helps you:
- Feel less hungry throughout the day
- Eat less without feeling deprived
- Gradually lose weight over time
- Benefit from better blood sugar control and cardiovascular health
Note: Sun Pharma markets two semaglutide brands in India - Noveltreat specifically for weight management, and Sematrinity for type 2 diabetes.
The scale of the problem in India
| Statistic | Figure |
|---|---|
| Indian adults who are overweight or obese | 1 in 4 (NFHS-5) |
| People with diabetes in India | 101.3 million (ICMR, 2023) |
| Diabetic patients not meeting HbA1c targets | 64% |
These numbers show just how urgent the need for effective, affordable treatment is. That is exactly where a generic medicine like Noveltreat can make a real difference.
How Noveltreat is Taken
Noveltreat comes in a prefilled pen device that is easy to hold, simple to use, and designed for self-injection at home. You inject it once a week, into the skin of your stomach, thigh, or upper arm. Most people find it far less painful than they expected.
Your doctor will not start you on the full dose straight away. The dose is gradually increased over several weeks - this is called dose escalation, and it helps your body adjust slowly so that side effects are minimised.
| Phase | Dose | Purpose |
|---|---|---|
| Starting dose | 0.25 mg/week | Help your body adjust |
| Step-up | 0.5 mg / 1 mg | Gradual increase |
| Higher step-up | 1.7 mg/week | Moving toward maintenance |
| Maintenance dose | 2.4 mg/week | Full therapeutic effect |
Noveltreat is available in five dose strengths: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg. Your doctor will decide which dose is right for you at each stage. Never change the dose on your own.
Noveltreat works best when combined with a calorie-reduced diet and regular physical activity. Always take it under the guidance of a qualified doctor.
What Results Can You Expect and When?
Results take time and vary from person to person. Here is a realistic timeline:
Weeks 1–4: Appetite may begin to reduce. You might feel full sooner during meals. Some people notice early blood sugar improvements. Weight changes at this stage are usually small.
Month 2–3: As the dose increases, weight loss becomes more noticeable and blood sugar control improves. Energy levels may start to improve.
Month 4–6: Most people see meaningful weight loss. Clinical studies with semaglutide 2.4 mg have shown significant body weight reductions over several months.
Beyond 6 months: Continued steady weight loss and metabolic improvements. Regular monitoring by your doctor is important.
Weight loss is not the only benefit. People taking semaglutide have also reported improvements in blood pressure, cholesterol, and overall cardiovascular health.
Common Side Effects
Like any medicine, Noveltreat can cause side effects. Most are mild and happen in the first few weeks as your body adjusts. They usually improve as the dose increases gradually.
Commonly reported:
- Nausea - the most common; usually gets better after the first few weeks
- Vomiting - less common, especially in early weeks
- Diarrhoea or constipation - changes in bowel habits
- Stomach discomfort or bloating - linked to slowed digestion
- Reduced appetite - the goal of the medicine, but can feel unfamiliar at first
- Headache or fatigue - occasionally reported early in treatment
Eating smaller, lighter meals helps reduce nausea. Staying well hydrated is important. If any side effect feels severe or does not improve, contact your doctor promptly.
Serious side effects are rare - including pancreatitis and vision changes in people with diabetes. Your doctor will monitor you for these.
How Noveltreat Compares to Ozempic and Wegovy
| Feature | Noveltreat (Sun Pharma) | Ozempic / Wegovy (Novo Nordisk) |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Type | Generic (post patent expiry) | Branded originator |
| Approved by | DCGI (India) | FDA (USA), EMA (Europe) |
| Expected cost | More affordable | Higher cost |
| Availability | India post patent expiry | Limited access in India |
| Clinical evidence | Phase III trial in India | Global clinical trials |
The biggest advantage of Noveltreat is that it is expected to be significantly more affordable than branded versions. Access to effective GLP-1 therapy has long been out of reach for most Indian patients due to cost. A DCGI-approved generic option changes that meaningfully.
As reported by Pharmacally and Express Pharma, Sun Pharma's DCGI approval follows a Phase III clinical trial conducted in India - meaning the safety and efficacy data is backed by evidence from Indian patients.
Kirti Ganorkar, Managing Director of Sun Pharma, has stated that the company is committed to improving access to generic semaglutide across India after patent expiry - a strong signal that affordability and reach are central to their plans.
Who Should Not Take Noveltreat?
Noveltreat is not suitable for everyone. Your doctor will review your full medical history before prescribing.
Avoid or use with caution if:
- Pregnant or breastfeeding - not recommended; inform your doctor if you are planning pregnancy
- Personal or family history of medullary thyroid carcinoma - semaglutide has been associated with thyroid tumours in animal studies
- Past or current pancreatitis - your doctor will assess the risk carefully
- Severe kidney or liver problems - these affect how your body processes the medicine
- Type 1 diabetes - Noveltreat is not indicated for type 1 diabetes
- Diabetic ketoacidosis - should not be used during this emergency
- Children and adolescents - approved for adults only
Medical supervision throughout treatment is essential. Never start or stop Noveltreat on your own.
Tracking Your Noveltreat Journey
Keeping a daily log of your weight, meals, blood sugar, and activity helps you and your doctor spot patterns and make better decisions. Small tracking habits lead to big changes over time.
WeightEasy supports semaglutide tracking for Indian users - log your weekly injection, weight trend, side effects, and food intake alongside your Noveltreat journey to get the clearest picture of your progress.
Final Takeaway
Noveltreat is Sun Pharma's DCGI-approved generic semaglutide for chronic weight management in adults. It contains the same active molecule as Ozempic and Wegovy, at a price point expected to be significantly more accessible for Indian patients. A Phase III clinical trial in India backs its safety and efficacy. Results typically begin appearing within the first month and build significantly over 4–6 months.
Always consult your healthcare provider before starting any medication.
Sources
- Sun Pharmaceutical Industries Limited. Sun Pharma receives DCGI approval for generic semaglutide injection. January 23, 2026. Official Press Release
- Pharmacally. Sun Pharma wins DCGI approval for Noveltreat generic semaglutide injection.
- Express Pharma. Sun Pharma receives DCGI approval to manufacture and market generic semaglutide injection in India.
- Collins L, Costello RA. Glucagon-Like Peptide-1 Receptor Agonists. StatPearls Publishing. 2024. PubMed / NCBI
- Drucker DJ. GLP-1-based therapies for diabetes, obesity and beyond. Nature Reviews Drug Discovery. 2025
FAQ
What is Noveltreat?
Noveltreat is Sun Pharma's brand name for generic semaglutide - a GLP-1 receptor agonist injection approved by India's DCGI for chronic weight management in adults. It is the weight-loss-specific brand; Sun Pharma's diabetes-focused brand is Sematrinity.
Is Noveltreat the same as Ozempic or Wegovy?
Yes - it contains the same active molecule, semaglutide. Noveltreat is a DCGI-approved generic made in India by Sun Pharma, which is expected to make it significantly more affordable than branded Ozempic or Wegovy, which are manufactured in Denmark by Novo Nordisk.
How fast does Noveltreat work?
Appetite reduction typically starts within the first few weeks. Visible weight loss is usually noticeable between weeks 4 and 12. Significant results appear after 4–6 months, especially when combined with diet and exercise.
Can non-diabetics take Noveltreat?
Yes. Noveltreat is approved specifically for chronic weight management in adults - including people without diabetes. You need a BMI of 30 or above (obesity), or BMI of 27 or above (overweight) with a related health condition, and a prescription from a qualified doctor.
What happens if I stop taking Noveltreat?
Research on semaglutide shows that some weight lost during treatment tends to return when the medicine is stopped, because appetite suppression goes away. This is why long-term lifestyle changes in diet and exercise are important alongside the medication.